Abbott Laboratories (ABT) Non Operating Income (2009 - 2026)

Abbott Laboratories has disclosed Non Operating Income across 18 years of filings, most recently posting $159.0 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $159.0 million, up 25.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $580.0 million (up 47.96% YoY), and the FY2025 annual result was $548.0 million, up 45.74% from the prior year.
• Non Operating Income came in at $159.0 million for Q1 2026 at Abbott Laboratories, up from $134.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $176.0 million in Q2 2023 to a low of -$10.0 million in Q2 2024.
• The 5-year median for Non Operating Income is $111.0 million (2023), against an average of $110.8 million.
• Across the five-year window, Non Operating Income plunged 105.68% in 2024 and jumped 1470.0% in 2025, its largest moves.
• Abbott Laboratories' Non Operating Income stood at $68.0 million in 2022, then surged by 60.29% to $109.0 million in 2023, then surged by 41.28% to $154.0 million in 2024, then retreated by 12.99% to $134.0 million in 2025, then increased by 18.66% to $159.0 million in 2026.
• The last three Non Operating Income figures came in at $159.0 million (Q1 2026), $134.0 million (Q4 2025), and $150.0 million (Q3 2025), per Business Quant data.